Drug intelligence / Profile preview

NerveTrace 800

Development stage: Unknown
Lead developer: Trace Biosciences
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

NerveTrace 800 is a small-molecule fluorescent nerve imaging agent developed by Trace Biosciences for intraoperative surgical guidance. It is specifically designed to visualize nerves during procedures such as colorectal surgery, prostatectomy, and hysterectomy. The agent is engineered for compatibility with standard indocyanine green (ICG) clinical imaging systems, enabling real-time visualization of nerve structures that might otherwise be obscured by tissue. By providing high-contrast fluorescence, NerveTrace 800 aims to reduce the risk of accidental nerve injury and improve surgical outcomes in complex pelvic and abdominal operations.

Brand names: NerveTrace 800NerveTrace800NerveTrace-800
Other names: NerveTrace

Beyond the preview

Go deeper on NerveTrace 800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NerveTrace 800.

Explore the full profile